HomepageCAMX • STO
add
Camurus AB
Vorige slotkoers
kr 670,50
Dag-range
kr 664,00 - kr 675,50
Jaar-range
kr 483,80 - kr 754,50
Beurswaarde
39,97 mld. SEK
Gem. volume
124,46K
Koers/winst
-
Dividendrendement
-
Primaire beurs
STO
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (SEK) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 567,07 mln. | 18,24% |
Bedrijfskosten | 297,52 mln. | -2,21% |
Netto inkomsten | 192,64 mln. | 48,93% |
Netto winstmarge | 33,97 | 25,95% |
Winst per aandeel | 3,19 | 47,69% |
EBITDA | 236,64 mln. | 62,61% |
Effectief belastingtarief | 21,46% | — |
Balans
Totale activa
Totale passiva
| (SEK) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 3,51 mld. | 27,75% |
Totale activa | 4,63 mld. | 29,73% |
Totale passiva | 510,02 mln. | 12,29% |
Totaal aandelenvermogen | 4,12 mld. | — |
Uitstaande aandelen | 59,61 mln. | — |
Koers-boekwaardeverhouding | 9,71 | — |
Rendement op activa | 12,72% | — |
Rendement op kapitaal | 14,04% | — |
Kasstroom
Nettomutatie in liquide middelen
| (SEK) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 192,64 mln. | 48,93% |
Operationele kasstroom | 160,46 mln. | 7,21% |
Kasstroom uit beleggingen | -31,18 mln. | -425,92% |
Kasstroom uit financiering | 39,36 mln. | -7,37% |
Nettomutatie in liquide middelen | 167,29 mln. | -9,15% |
Vrije kasstroom | 17,16 mln. | -72,69% |
Over
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Opgericht
1991
Website
Werknemers
280
